Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders that redirect the cell’s protein-disposal machinery toward disease-causing proteins. The approach aims at targets that are hard to drug with traditional small-molecule inhibitors, with programs spanning oncology and other serious diseases. Its platform combines chemistry, structural biology and computational design to invent glue molecules that induce selective protein degradation.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 84.9 | — | 46.9 | — |
| Q2 2025 | 23.2 | — | -12.3 | — |
| Q3 2025 | 12.8 | — | -27.1 | — |
| Q4 2025 | 2.8 | — | -46.1 | — |
| Q1 2026 | 4.2 | -95% | -44.5 | -194.9% |
| Q2 2026 | 9 | -61.3% | -43.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Daily Journal Corporation (DJCO), Strategy Inc (STRD), Liberty Capital Corporation (GLIBK), Sify Technologies Limited (SIFY), Odyssey Therapeutics, Inc. (ODTX), Westrock Coffee Company (WEST)